StonvexLoading…
StonvexStonvexStonvexCore line items from SYRE's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Q3 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-209.56M | $-208.57M | $-147.31M | $-91.92M |
Net Income | $-155.20M | $-208.02M | $-151.72M | $-38.84M |
EPS (Diluted) | Not available | Not available | $2.39 | $1.31 |
Total Assets | $777.78M | $608.48M | $421.09M | $436.07M |
Total Liabilities | $62.55M | $90.68M | $93.70M | $61.68M |
Cash & Equivalents | $85.72M | $89.42M | $71.58M | $45.14M |
Free Cash Flow OCF − CapEx | Not available | $-157.41M | Not available | Not available |
Shares Outstanding | 78.19M | 60.26M | 51.40M | 50.78M |